Closes previously announced clinical trials laboratory services joint venture transaction.
Researchers have developed a novel method to detect drug resistant hepatitis C virus mutants that could provide key information for the prediction of disease progression.
Randox has invested £15 million in R&D from 2014-2015, allowing for the creation of a bold new division – Randox Biosciences – creating 30 new staff. This new venture has an international focus targeting – Japan, USA, Europe and other key markets.
Novel test could predict efficacy of biologics for rheumatoid arthritis.
New tool utilizes optical components of smartphone to conduct biomolecular test.
A breath test that could help doctors rapidly diagnose oesophageal and gastric cancer has been developed.
New MS-based technology developed for faster biopsy analysis.
Collaboration with Thermo Fisher, Gladstone, UCSF, and QB3 to focus on accelerating disease research using advanced proteomics technologies.
Researchers are in the early stages of developing a breath test for respiratory tract infections in critically ill patients.
Method of obtaining more accurate data from glucometers could have potential for human diabetics.